生物醫藥技術全國重點實驗室
（香港大學）
State Key Laboratory of Pharmaceutical Biotechnology
（The University of Hong Kong)
Field of Research
Antibody drug development and In Vitro Diagnostic (IVD) reagent development
Biography
Dr. Hu received his bachelor’s degree in 2015 from the Wuhan Institute of Technology and his master’s degree in 2016 from the Chinese University of Hong Kong. In 2023, he was awarded his Ph.D. from the State Key Laboratory of Pharmaceutical Technology at the University of Hong Kong. He is currently a Post-doctoral Fellow under the supervision of Professor Aimin Xu, where his research focuses on antibody drug development and In Vitro Diagnostic (IVD) reagent development.
Publications
-
Qiu H, Song E, Hu Y, Li T, Ku KC, Wang C, Cheung BMY, Cheong LY, Wang Q, Wu X, Hoo RLC, Wang Y, Xu A. Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPARα/FGF21 Axis. Cell Mol Gastroenterol Hepatol. 2022;14(5):1003-1023. (Co-first author, IF: 9.225)
-
Yang R, Hu Y, Lee CH, Liu Y, Diaz-Canestro C, Fong CHY, Lin H, Cheng KKY, Pravelil AP, Song E, Lam KSL, Xu A. PM20D1 is a circulating biomarker closely associated with obesity, insulin resistance, and metabolic syndrome. Eur J Endocrinol. 2021 Dec 10;186(2):151-161. (Co-first author, IF:6.664)
-
Jia X, Song E, Liu Y, Chen J, Wan P, Hu Y, Ye D, Chakrabarti S, Mahajan H, George J, Yan S, Yu Y, Zhang G, Wang Y, Yang W, Wu L, Hua S, Lee CH, Li H, Jiang X, Lam KSL, Wang C, Xu A. Identification and multicentric validation of soluble CDCP1 as a robust serological biomarker for risk stratification of NASH in obese Chinese. Cell Rep Med. 2023 Oct 26:101257. (6th author, IF: 16.988)
Patents: CN 104447613 A; CN 104983717 A; CN 104983696 A; CN 104983696 A; CN 104983706A